HCPLive 5 Stories in Under 5: Week of 05/11
No se pudo agregar al carrito
Solo puedes tener X títulos en el carrito para realizar el pago.
Add to Cart failed.
Por favor prueba de nuevo más tarde
Error al Agregar a Lista de Deseos.
Por favor prueba de nuevo más tarde
Error al eliminar de la lista de deseos.
Por favor prueba de nuevo más tarde
Error al añadir a tu biblioteca
Por favor intenta de nuevo
Error al seguir el podcast
Intenta nuevamente
Error al dejar de seguir el podcast
Intenta nuevamente
HCPLive 5 Stories in Under 5: Week of 05/11
-
Narrado por:
-
De:
Acerca de esta escucha
Interested in a more traditional, text rundown? Check out the HCPFive!
Top 5 Healthcare Headlines for May 5- 11, 2025:
FDA Accepts Sparsentan (Filspari) sNDA for Focal Segmental Glomerulosclerosis
The FDA will review Travere Therapeutics’ application for full approval of sparsentan in FSGS, with an advisory committee meeting planned ahead of a January 2026 decision.
FDA Accepts BioCryst’s NDA for Berotralstat Oral Granules in Children With HAE
The FDA is evaluating berotralstat oral granules for pediatric hereditary angioedema, which could become the first oral preventive therapy for children under 12.
SURMOUNT-5: Tirzepatide (Zepbound) Proves Benefit over Semaglutide (Wegovy) for Obesity
Tirzepatide demonstrated superior weight loss outcomes compared with semaglutide in the SURMOUNT-5 trial for patients with obesity.
Crinecerfont Reduces Steroid Use for Pediatric CAH in Phase 3 Analysis
Crinecerfont lowered steroid requirements while maintaining hormone control in children with classic congenital adrenal hyperplasia, regardless of baseline characteristics.
Type 1 Diabetes Diagnosed in Adulthood Heightens Cardiovascular Risk
Adults diagnosed with type 1 diabetes face increased cardiovascular and all-cause mortality risks, regardless of age at diagnosis, according to long-term national data.
Todavía no hay opiniones